Mounjaro and Ozempic are two once-weekly injections that are easy to confuse because they are prescribed in similar settings, but they are different molecules. Mounjaro is a brand of tirzepatide, a GLP-1 and GIP dual agonist, while Ozempic is a brand of semaglutide, a GLP-1 agonist. Both are FDA-approved for type 2 diabetes, so this comparison is about their mechanism and the one trial that tested them directly.
Reviewed for accuracy · Last reviewed July 7, 2026The one direct head-to-head is SURPASS-2, a Phase 3 diabetes trial that compared tirzepatide against semaglutide 1 mg over 40 weeks. Tirzepatide reduced HbA1c more in that trial, but that is a specific diabetes endpoint at a specific semaglutide dose, not a general statement that Mounjaro is better than Ozempic for everyone.
Mechanistically, Mounjaro's tirzepatide adds the GIP receptor to the GLP-1 target that Ozempic's semaglutide uses. Both slow gastric emptying and reduce appetite, both are dosed as once-weekly subcutaneous injections with gradual titration, and both carry the same class boxed warning for thyroid C-cell tumors.
Practical differences often come down to product, tolerability, insurance coverage, and access rather than molecule alone. Which is appropriate is a medical decision, and independently sourced vials of either carry no guarantee of the testing a regulated product does.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.